In this part of his Pharmaceutical Executive video interview, Dr. Lawrence B. Werlin, MD, FACOG of HRC Fertility (@md.lawrence.werlin on TikTok), explains the ethical considerations of using social media to share personal and professional experiences, especially in a field as sensitive as fertility.
In this Pharmaceutical Executive video interview, Dr. Lawrence B. Werlin, MD, FACOG of HRC Fertility (@md.lawrence.werlin on TikTok), discusses the challenges of addressing fertility misinformation on social media. He emphasizes the importance of providing accurate and reliable information and encourages patients to consult with healthcare professionals. He also discusses the ethical considerations of using social media to share personal and professional experiences in the field of fertility.
The important factors that you have to take into account is that when I, for example, utilize social media, I tell the patients or the people who are listening right up front that these are my opinions. These are my thoughts. This is how I would manage a specific case. And again, medicine is an art, and there are multiple ways to do things, and it's important to take into account that there are many ways that you can address a certain situation, and each doctor may be different, and you have to take that into account. So that's really the first thing I think that's important. I tell the patients that when I do this, I think the other thing that's critical is that just because I say that doesn't mean that patients will believe that. They may think that, ‘well, this is the only way to do it, and I need to do it that way.’ And that's not always the case. The reality is that there are different ways of approaching problems, and really what your physician outlines for you, hopefully, is the best approach that you can do. But your options, of course, are that if you don't feel it's the best, you can always seek another opinion, and many times, social media offers that second opinion type situation.
With respect to anonymity, I think that it is important for people to observe their own anonymity, because otherwise it sets up problems that could occur for them. It's not an unusual thing for a patient to say, ‘I am a 32-year-old woman. I've been trying to get pregnant for X amount of years. I've been unsuccessful. I've done a number of procedures.’ That's fine, but I certainly would encourage them to not necessarily use their name, necessarily use the facility that they're working with. I would keep it as broad as possible, so as not to incur any problems with respect to anonymity. And with HIPAA rule, HIPAA violations, is very important to keep patient confidentiality at the peak.
IMF Chief Medical Officer Discusses Global Initiatives to Improve Myeloma Treatment
August 20th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Joseph Mikhael, chief medical officer, IMF, offers a glimpse at multiple initiatives that the IMF is working towards to improve myeloma treatment globally.
AbbVie Presents New Data from Antibody-Drug Conjugates Across Multiple Indications at ASCO 2024
June 13th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Pedro Valencia, VP, Solid Tumor Pipeline Strategy & Execution, AbbVie, discusses data presented at ASCO from ABBV-400 and ABBV-706 in multiple studies.
Planning for Unique Challenges Faced by Cell & Gene Therapy Developers
May 8th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Melissa Lattanzi, VP, Emerging Therapies, Cencora, discusses the unique challenges that developers of cell and gene therapies need to plan for when building their channel strategy.
Pricing Climate Impacting Commercial Considerations
May 3rd 2024In this Pharmaceutical Executive video interview, Jesse Mendelsohn, senior vice president at Model N, talks about the influence of Medicare Part D drug price negotiations on manufacturer go-to-market strategies and decision-making, and the industry’s response to the wider dialogue on pricing transparency.
IMF Chief Medical Officer Discusses Global Initiatives to Improve Myeloma Treatment
August 20th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Joseph Mikhael, chief medical officer, IMF, offers a glimpse at multiple initiatives that the IMF is working towards to improve myeloma treatment globally.
AbbVie Presents New Data from Antibody-Drug Conjugates Across Multiple Indications at ASCO 2024
June 13th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Pedro Valencia, VP, Solid Tumor Pipeline Strategy & Execution, AbbVie, discusses data presented at ASCO from ABBV-400 and ABBV-706 in multiple studies.
Planning for Unique Challenges Faced by Cell & Gene Therapy Developers
May 8th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Melissa Lattanzi, VP, Emerging Therapies, Cencora, discusses the unique challenges that developers of cell and gene therapies need to plan for when building their channel strategy.
Pricing Climate Impacting Commercial Considerations
May 3rd 2024In this Pharmaceutical Executive video interview, Jesse Mendelsohn, senior vice president at Model N, talks about the influence of Medicare Part D drug price negotiations on manufacturer go-to-market strategies and decision-making, and the industry’s response to the wider dialogue on pricing transparency.
2 Commerce Drive
Cranbury, NJ 08512